143 related articles for article (PubMed ID: 12672226)
1. A novel N-terminal cyclic dynorphin A analogue cyclo(N,5)[Trp(3),Trp(4),Glu(5)] dynorphin A-(1-11)NH(2) that lacks the basic N-terminus.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2003 Apr; 46(8):1279-82. PubMed ID: 12672226
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
[TBL] [Abstract][Full Text] [Related]
3. [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist.
Patkar KA; Yan X; Murray TF; Aldrich JV
J Med Chem; 2005 Jul; 48(14):4500-3. PubMed ID: 15999987
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of novel basic head-to-side-chain cyclic dynorphin A analogs: strategies and side reactions.
Vig BS; Murray TF; Aldrich JV
Biopolymers; 2003; 71(6):620-37. PubMed ID: 14991673
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.
Arttamangkul S; Ishmael JE; Murray TF; Grandy DK; DeLander GE; Kieffer BL; Aldrich JV
J Med Chem; 1997 Apr; 40(8):1211-8. PubMed ID: 9111295
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
Choi H; Murray TF; DeLander GE; Schmidt WK; Aldrich JV
J Med Chem; 1997 Aug; 40(17):2733-9. PubMed ID: 9276018
[TBL] [Abstract][Full Text] [Related]
8. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
9. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.
Przydzial MJ; Pogozheva ID; Bosse KE; Andrews SM; Tharp TA; Traynor JR; Mosberg HI
J Pept Res; 2005 Mar; 65(3):333-42. PubMed ID: 15787963
[TBL] [Abstract][Full Text] [Related]
10. Identification of arodyn, a novel acetylated dynorphin A-(1-11) analogue, as a kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Med Chem; 2002 Dec; 45(26):5617-9. PubMed ID: 12477343
[TBL] [Abstract][Full Text] [Related]
11. The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
Patkar KA; Murray TF; Aldrich JV
J Med Chem; 2009 Nov; 52(21):6814-21. PubMed ID: 19807094
[TBL] [Abstract][Full Text] [Related]
12. Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Dolle RE; Michaut M; Martinez-Teipel B; Seida PR; Ajello CW; Muller AL; DeHaven RN; Carroll PJ
Bioorg Med Chem Lett; 2009 Jul; 19(13):3647-50. PubMed ID: 19464172
[TBL] [Abstract][Full Text] [Related]
13. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
Vig BS; Zheng MQ; Murray TF; Aldrich JV
J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological activities of cyclic lactam peptide analogues of dynorphine A(1-11)-NH2.
Lung FD; Collins N; Stropova D; Davis P; Yamamura HI; Porreca F; Hruby VJ
J Med Chem; 1996 Mar; 39(5):1136-41. PubMed ID: 8676350
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides.
Rivier JE; Kirby DA; Erchegyi J; Waser B; Eltschinger V; Cescato R; Reubi JC
J Med Chem; 2005 Jan; 48(2):515-22. PubMed ID: 15658865
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of novel cyclic alpha-MSH/beta-MSH hybrid analogues that lead to potent and selective ligands for the human MC3R and human MC5R.
Balse-Srinivasan P; Grieco P; Cai M; Trivedi D; Hruby VJ
J Med Chem; 2003 Aug; 46(17):3728-33. PubMed ID: 12904077
[TBL] [Abstract][Full Text] [Related]
17. Development of highly potent and selective dynorphin A analogues as new medicines.
Lung FD; Chen CH; Liu JH
J Pept Res; 2005 Nov; 66(5):263-76. PubMed ID: 16218994
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of dynorphin a analogues modified in the address sequence.
Schlechtingen G; DeHaven RN; Daubert JD; Cassel JA; Chung NN; Schiller PW; Taulane JP; Goodman M
J Med Chem; 2003 May; 46(11):2104-9. PubMed ID: 12747782
[TBL] [Abstract][Full Text] [Related]
19. Dynorphin A analogs containing a conformationally constrained phenylalanine derivative in position 4: reversal of preferred stereochemistry for opioid receptor affinity and discrimination of kappa vs. delta receptors.
Aldrich JV; Zheng QI; Murray TF
Chirality; 2001; 13(3):125-9. PubMed ID: 11270320
[TBL] [Abstract][Full Text] [Related]
20. Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 2: effects of substitutions on pharmacological activity.
Fang WJ; Bennett MA; Murray TF; Aldrich JV
Biopolymers; 2011; 96(1):103-10. PubMed ID: 20560148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
